Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sacubitril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 13/20 | 0.77 |
| ▸ | ACE | P12821 | 4/20 | 0.77 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sacubitril SCHEMBL489040 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL22420467 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL2707112 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18574632 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239958 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239955 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL17746036 | 0.99 | MME (0.76) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872249-B2 | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain | NOVARTIS AG (CH) | 2024-01-16 | — | — | US | disclosed |
| US-20230374105-A1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | NOVARTIS AG (CH) | 2023-11-23 | — | — | US | disclosed |
| US-11786498-B2 | Sacubitril calcium salts | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11786498-B2 | Sacubitril calcium salts | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-11026976-B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-10857132-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | LAURUS LABS LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-10851059-B2 | Processes and intermediates for NEP inhibitor synthesis | NOVARTIS AG (CH) | 2020-12-01 | — | — | US | disclosed |
| US-20200277266-A1 | SOLID STATE FORMS OF TRISODIUM VALSARTAN: SACUBITRIL | TEVA PHARMACEUTICALS INT GMBH (CH) | 2020-09-03 | — | — | US | disclosed |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-11026976-B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | CD22, CD2, CD209 | MME 959/4885ACE 1633/4885MMEL1 307/4885 |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | MME 1/4885ACE 5/4885MMEL1 776/4885 |
| US-20200277266-A1 | SOLID STATE FORMS OF TRISODIUM VALSARTAN: SACUBITRIL | ACE, AGT, REN | MME 18/4885ACE 1/4885MMEL1 1453/4885 |
| US-10857132-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | AGT, ACE, REN | MME 26/4885ACE 2/4885MMEL1 2441/4885 |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | MME 1/4885ACE 5/4885MMEL1 697/4885 |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | MME 16/4885ACE 2/4885MMEL1 397/4885 |
| US-20230374105-A1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | CD22, CD2, CD99 | MME 1302/4885ACE 2023/4885MMEL1 459/4885 |
| US-10851059-B2 | Processes and intermediates for NEP inhibitor synthesis | MME, ACE, DNPEP | MME 1/4885ACE 2/4885MMEL1 117/4885 |
| US-11872249-B2 | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain | CD22, CD2, FCGR1A | MME 469/4885ACE 1476/4885MMEL1 182/4885 |
| US-11786498-B2 | Sacubitril calcium salts | DNPEP, BPGM, CACNA1S | MME 8/4885ACE 31/4885MMEL1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.